Search

Purpose of this review: Manipulating or re-engineering the damaged human spinal cord to achieve neuro-recovery is one of the foremost challenges of modern science. Addressing the restricted permission of neural cells and topographically organised neural tissue for self-renewal and spontaneous regeneration, respectively, is not straightforward, as exemplified by rare instances of translational success. This review assembles an understanding of advances in nanomedicine for spinal cord injury (SCI) and related clinical indications of relevance to attempts to design, engineer, and target nanotechnologies to multiple molecular networks. Recent findings: Recent research provides a new understanding of the health benefits and regulatory landscape of nanomedicines based on a background of advances in mRNA-based nanocarrier vaccines and quantum dot-based optical imaging. In relation to spinal cord pathology, the extant literature details promising advances in nanoneuropharmacology and regenerative medicine that inform the present understanding of the nanoparticle (NP) biocompatibility–neurotoxicity relationship. In this review, the conceptual bases of nanotechnology and nanomaterial chemistry covering organic and inorganic particles of sizes generally less than 100 nm in diameter will be addressed. Regarding the centrally active nanotechnologies selected for this review, attention is paid to NP physico-chemistry, functionalisation, delivery, biocompatibility, biodistribution, toxicology, and key molecular targets and biological effects intrinsic to and beyond the spinal cord parenchyma. Summary: The advance of nanotechnologies for the treatment of refractory spinal cord pathologies requires an in-depth understanding of neurobiological and topographical principles and a consideration of additional complexities involving the research’s translational and regulatory landscapes.

Paclitaxel (PTX) and 5-fluorouracil (5-FU) are clinically relevant chemotherapeutics, but both suffer a range of biopharmaceutical challenges (e.g., either low solubility or permeability and limited controlled release from nanocarriers), which reduces their effectiveness in new medicines. Anticancer drugs have several major limitations, which include non-specificity, wide biological distribution, a short half-life, and systemic toxicity. Here, we investigate the potential of liposome-micelle-hybrid (LMH) carriers (i.e., drug-loaded micelles encapsulated within drug-loaded liposomes) to enhance the co-formulation and delivery of PTX and 5-FU, facilitating new delivery opportunities with enhanced chemotherapeutic performance. We focus on the combination of liposomes and micelles for co-delivery of PTX and 5_FU to investigate increased drug loading, improved solubility, and transport/permeability to enhance chemotherapeutic potential. Furthermore, combination chemotherapy (i.e., containing two or more drugs in a single formulation) may offer improved pharmacological performance. Compared with individual liposome and micelle formulations, the optimized PTX-5FU-LMH carriers demonstrated increased drug loading and solubility, temperature-sensitive release, enhanced permeability in a Caco-2 cell monolayer model, and cancer cell eradication. LMH has significant potential for cancer drug delivery and as a next-generation chemotherapeutic.

Quantum dot-based NO2 sensors often suffer from low sensitivity or long recovery times. Here, the authors report that bimetallic PbCdSe quantum dot gels containing atomically dispersed Pb ionic sites enable ultra-sensitive and fast NO2 sensing.

This paper describes the synthesis of a new type of nanowires, potassium tetracyanoplatinate sesquihydrate Krogmann salt or K(def)TCP. Seed-mediated electrocrystallization nucleates and confines the K(def)TCP crystals into nanowires. Our data show that the width of K(def)TCP scales proportionally with the diameter of the seed, which is consistent with the nanoconfinement effect of the seed. K(def)TCP nanowires are also electrodeposited on lithographic Au patterns as interconnects and tested for impedance-based gas sensing. The results demonstrate the use of electrocrystallization to construct nanowire sensing units directly on patterned substrates to enable scaling up of nanowire sensor technology. IMPACT STATEMENT We show for the first time nanowires directly formed as interconnects on electronic substrates by electrocrystallization are used as sensor materials to detect gases.

Abstract Electrocrystallization is a promising method for controlled charge‐transfer complex (CTC) deposition on microfabricated electrodes for gas sensing applications. However, there remains a gap in our understanding of CTC electrodeposition. In this study, we focus on investigating the electrocrystallization of cobalt tetracyanoquinodimethane (Co‐TCNQ) on a microdisk electrode to elucidate and control the process. Leveraging the microelectrode technique, we conduct steady‐state measurements to observe nucleation and crystal growth dynamics, particularly in the early stages of electrocrystallization. We use cyclic voltammetry and chronoamperometry to examine Co‐TCNQ electrocrystallization under various electrolytic conditions. We identify electrocrystallization kinetics, ranging from electrokinetic to diffusion‐limited growth, governing the nucleation and growth of Co‐TCNQ crystals. Notably, we pinpoint the applied overpotential and precursor concentration range necessary for a single nucleation site on the microelectrode. Moreover, we demonstrate control over crystal orientation and morphology. Our findings reveal a nonclassical growth pathway for Co‐TCNQ crystals characterized by oriented attachment of small crystallites along the conductive long axis. Importantly, electrodeposited Co‐TCNQ on patterned microelectrodes exhibits selective sensing capabilities for nitrogen dioxide gas. Overall, this study sheds light on CTC electrodeposition through a proof‐of‐concept demonstration involving Co‐TCNQ electrodeposition on microelectrodes, presenting potential applications across diverse materials.